The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Open accessAbstract
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T cells (TCR T). Unlike chimeric antigen receptors (CARs), TCRs recognize HLA-presented peptides derived from proteins of all cellular compartments. The use of TCR T cells for adoptive cellular therapies (ACT) has gained increased attention, especially as efforts to treat solid cancers with ACTs have intensified. In this review, we describe the differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs. We describe the classes of cancer antigens recognized by current TCR T therapies and discuss both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation. Finally, we review the current landscape of clinical trials for TCR T therapy and discuss what these current results indicate for the development of future engineered TCR approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Worldwide burden of cancer attributable to HPV by site, country and HPV type
de Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017) · International Journal of Cancer · doi:10.1002/ijc.30716 · Cited by 2,322
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
The IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,740
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
HOW TCRS BIND MHCS, PEPTIDES, AND CORECEPTORS
Rudolph, M. G., Stanfield, R. L., & Wilson, I. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115658 · Cited by 1,310
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,019
Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 969
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
The proteasome: overview of structure and functions
TANAKA, K. (2009) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.85.12 · Cited by 862
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Reprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Thompson, M. P., & Kurzrock, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0670-3 · Cited by 786
Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 773
Gonzalez-Galarza, F. F., McCabe, A., Santos, E. J. M. D., Jones, J., Takeshita, L., Ortega-Rivera, N. D., Cid-Pavon, G. M. D., Ramsbottom, K., Ghattaoraya, G., Alfirevic, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1029 · Cited by 731
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729
Cameron, B. J., Gerry, A. B., Dukes, J., Harper, J. V., Kannan, V., Bianchi, F. C., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 684
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Reusser, P., Riddell, Sr., Meyers, J., & Greenberg, P. (1991) · Blood · doi:10.1182/blood.v78.5.1373.1373 · Cited by 666
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Pal, A., & Kundu, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03116 · Cited by 597
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
Transfer of specificity by murine α and β T-cell receptor genes
DembiĆ, Z., Haas, W., Weiss, S., McCubrey, J., Kiefer, H., von Boehmer, H., & Steinmetz, M. (1986) · Nature · doi:10.1038/320232a0 · Cited by 579
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Self-citationRiddell, S. R., Elliott, M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overell, R. W., Reynolds, T. C., Corey, L., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-216 · Cited by 565
Role of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Bollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
Current Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
Mechanisms for T cell receptor triggering
van der Merwe, P. A., & Dushek, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri2887 · Cited by 482
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1450 · Cited by 469
Tzannou, I., Papadopoulou, A., Naik, S., Leung, K., Martinez, C. A., Ramos, C. A., Carrum, G., Sasa, G., Lulla, P., Watanabe, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0655 · Cited by 457
The Role of HPV E6 and E7 Oncoproteins in HPV-associated Cervical Carcinogenesis
Yim, E.-K., & Park, J.-S. (2005) · Cancer Research and Treatment · doi:10.4143/crt.2005.37.6.319 · Cited by 453
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D. M., Pouw, N., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 448
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Directed evolution of human T-cell receptors with picomolar affinities by phage display
Li, Y., Moysey, R., Molloy, P. E., Vuidepot, A.-L., Mahon, T., Baston, E., Dunn, S., Liddy, N., Jacob, J., Jakobsen, B. K., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1070 · Cited by 442
D'Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D., Glod, J., Kaplan, R., Grupp, S., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 435
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Almeida, L. G., Sakabe, N. J., deOliveira, A. R., Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y.-T., Chua, R., Gurung, S., Gnjatic, S., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 433
Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., & Greenberg, P. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1637 · Cited by 428
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Morel, S., Lévy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A.-L., Monsarrat, B., Van Velthoven, R., Cerottini, J.-C., Boon, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80163-6 · Cited by 415
Lu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Frey, N., & Porter, D. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.756 · Cited by 399
Prediction of the human membrane proteome
Fagerberg, L., Jonasson, K., von Heijne, G., Uhlén, M., & Berglund, L. (2010) · PROTEOMICS · doi:10.1002/pmic.200900258 · Cited by 397
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
Robbins, P. F., Li, Y. F., El-Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 383
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia
Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., et al. (1997) · Blood · doi:10.1182/blood.v89.4.1405 · Cited by 371
The in silico human surfaceome
Bausch-Fluck, D., Goldmann, U., Müller, S., van Oostrum, M., Müller, M., Schubert, O. T., & Wollscheid, B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808790115 · Cited by 369
T‐cell receptor binding affinities and kinetics: impact on T‐cell activity and specificity
Stone, J. D., Chervin, A. S., & Kranz, D. M. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03015.x · Cited by 367
Facilitating matched pairing and expression of TCR chains introduced into human T cells
Kuball, J., Dossett, M. L., Wolfl, M., Ho, W. Y., Voss, R.-H., Fowler, C., & Greenberg, P. D. (2007) · Blood · doi:10.1182/blood-2006-05-023069 · Cited by 365
Cohen, C. J., Li, Y. F., El-Gamil, M., Robbins, P. F., Rosenberg, S. A., & Morgan, R. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3986 · Cited by 361
Dawson, C. W., Port, R. J., & Young, L. S. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.004 · Cited by 355
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nagarsheth, N. B., Norberg, S. M., Sinkoe, A. L., Adhikary, S., Meyer, T. J., Lack, J. B., Warner, A. C., Schweitzer, C., Doran, S. L., Korrapati, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01225-1 · Cited by 345
IL-15 Promotes the Survival of Naive and Memory Phenotype CD8+ T Cells
Berard, M., Brandt, K., Paus, S. B., & Tough, D. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5018 · Cited by 343
Avanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D. P., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 341
Immune response to green fluorescent protein: implications for gene therapy
Stripecke, R., del Carmen Villacres, M., Skelton, D. C., Satake, N., Halene, S., & Kohn, D. B. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300951 · Cited by 333
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Chapuis, A. G., Egan, D. N., Bar, M., Schmitt, T. M., McAfee, M. S., Paulson, K. G., Voillet, V., Gottardo, R., Ragnarsson, G. B., Bleakley, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0472-9 · Cited by 329
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Heczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Minimal functional driver gene heterogeneity among untreated metastases
Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Heyde, A., Attiyeh, M. A., Kohutek, Z. A., Tokheim, C. J., Brown, A., DeBlasio, R. M., Niyazov, J., et al. (2018) · Science · doi:10.1126/science.aat7171 · Cited by 307
Shum, T., Omer, B., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0538 · Cited by 297
In vitro evolution of a T cell receptor with high affinity for peptide/MHC
Holler, P. D., Holman, P. O., Shusta, E. V., O'Herrin, S., Wittrup, K. D., & Kranz, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080078297 · Cited by 295
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
Zhao, Y., Zheng, Z., Cohen, C. J., Gattinoni, L., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.688 · Cited by 283
Lu, Y.-C., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 279
Doran, S. L., Stevanović, S., Adhikary, S., Gartner, J. J., Jia, L., Kwong, M. L. M., Faquin, W. C., Hewitt, S. M., Sherry, R. M., Yang, J. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02424 · Cited by 272
Chodon, T., Comin-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 259
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250
Zhong, S., Malecek, K., Johnson, L. A., Yu, Z., Vega-Saenz de Miera, E., Darvishian, F., McGary, K., Huang, K., Boyer, J., Corse, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221609110 · Cited by 245
Cilloni, D., Gottardi, E., De Micheli, D., Serra, A., Volpe, G., Messa, F., Rege-Cambrin, G., Guerrasio, A., Divona, M., Lo Coco, F., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402675 · Cited by 245
Cellular networks controlling T cell persistence in adoptive cell therapy
Chan, J. D., Lai, J., Slaney, C. Y., Kallies, A., Beavis, P. A., & Darcy, P. K. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00539-6 · Cited by 243
Watanabe, K., Kuramitsu, S., Posey, A. D., & June, C. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02486 · Cited by 242
Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human Cancers
Balch, C. M. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410140078012 · Cited by 241
T CELL RECEPTOR GENE DIVERSITY AND SELECTION
Davis, M. M. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.002355 · Cited by 241
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240
Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010
Khan, G., & Hashim, M. J. (2014) · Infectious Agents and Cancer · doi:10.1186/1750-9378-9-38 · Cited by 240
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Ajina, A., & Maher, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1097 · Cited by 237
Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
Inozume, T., Hanada, K.-I., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 233
Mixed T cell receptor dimers harbor potentially harmful neoreactivity
van Loenen, M. M., de Boer, R., Amir, A. L., Hagedoorn, R. S., Volbeda, G. L., Willemze, R., van Rood, J. J., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005802107 · Cited by 232
Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor.
Minami, Y., Weissman, A. M., Samelson, L. E., & Klausner, R. D. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.2688 · Cited by 232
Human Tumor Antigens and Cancer Immunotherapy
Vigneron, N. (2015) · BioMed Research International · doi:10.1155/2015/948501 · Cited by 228
Riddell, S. R., Rabin, M., Geballe, A. P., Britt, W. J., & Greenberg, P. D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.8.2795 · Cited by 226
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
Wang, S., Sun, J., Chen, K., Ma, P., Lei, Q., Xing, S., Cao, Z., Sun, S., Yu, Z., Liu, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02006-4 · Cited by 222
Zhao, Y., Bennett, A. D., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L. Y. L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 220
Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function
Schmid, D. A., Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J.-C. F., Gomez-Eerland, R., Thome, M., Schumacher, T. N. M., Romero, P., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000173 · Cited by 219
Lai, J., Mardiana, S., House, I. G., Sek, K., Henderson, M. A., Giuffrida, L., Chen, A. X. Y., Todd, K. L., Petley, E. V., Chan, J. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0676-7 · Cited by 219
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217
Guillaume, B., Chapiro, J., Stroobant, V., Colau, D., Van Holle, B., Parvizi, G., Bousquet-Dubouch, M.-P., Théate, I., Parmentier, N., & Van den Eynde, B. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009778107 · Cited by 216
The ABCs of artificial antigen presentation
Kim, J. V., Latouche, J.-B., Rivière, I., & Sadelain, M. (2004) · Nature Biotechnology · doi:10.1038/nbt955 · Cited by 192
Pasetto, A., Gros, A., Robbins, P. F., Deniger, D. C., Prickett, T. D., Matus-Nicodemos, R., Douek, D. C., Howie, B., Robins, H., Parkhurst, M. R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0001 · Cited by 190
CAR models: next-generation CAR modifications for enhanced T-cell function
Abate-Daga, D., & Davila, M. L. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.14 · Cited by 187
Targeting public neoantigens for cancer immunotherapy
Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 187
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Draper, L. M., Kwong, M. L. M., Gros, A., Stevanović, S., Tran, E., Kerkar, S., Raffeld, M., Rosenberg, S. A., & Hinrichs, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3341 · Cited by 183
An engineered IL-2 partial agonist promotes CD8+ T cell stemness
Mo, F., Yu, Z., Li, P., Oh, J., Spolski, R., Zhao, L., Glassman, C. R., Yamamoto, T. N., Chen, Y., Golebiowski, F. M., et al. (2021) · Nature · doi:10.1038/s41586-021-03861-0 · Cited by 183
Parkhurst, M., Gros, A., Pasetto, A., Prickett, T., Crystal, J. S., Robbins, P., & Rosenberg, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2680 · Cited by 182
Harris, D. T., Hager, M. V., Smith, S. N., Cai, Q., Stone, J. D., Kruger, P., Lever, M., Dushek, O., Schmitt, T. M., Greenberg, P. D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700236 · Cited by 182
Kageyama, S., Ikeda, H., Miyahara, Y., Imai, N., Ishihara, M., Saito, K., Sugino, S., Ueda, S., Ishikawa, T., Kokura, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1559 · Cited by 179
How many TCR clonotypes does a body maintain?
Lythe, G., Callard, R. E., Hoare, R. L., & Molina-París, C. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.10.016 · Cited by 175
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Shah, N. N., Maatman, T., Hari, P., & Johnson, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00146 · Cited by 173
Tawara, I., Kageyama, S., Miyahara, Y., Fujiwara, H., Nishida, T., Akatsuka, Y., Ikeda, H., Tanimoto, K., Terakura, S., Murata, M., et al. (2017) · Blood · doi:10.1182/blood-2017-06-791202 · Cited by 171
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR
Willemsen, R. A., Weijtens, M. E. M., Ronteltap, C., Eshhar, Z., Gratama, J. W., Chames, P., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301253 · Cited by 170
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Jin, B. Y., Campbell, T. E., Draper, L. M., Stevanović, S., Weissbrich, B., Yu, Z., Restifo, N. P., Rosenberg, S. A., Trimble, C. L., & Hinrichs, C. S. (2018) · JCI Insight · doi:10.1172/jci.insight.99488 · Cited by 168
Value and affordability of CAR T-cell therapy in the United States
Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 166
Cafri, G., Yossef, R., Pasetto, A., Deniger, D. C., Lu, Y.-C., Parkhurst, M., Gartner, J. J., Jia, L., Ray, S., Ngo, L. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08304-z · Cited by 165
Landscape of Tumor Antigens in T Cell Immunotherapy
Ilyas, S., & Yang, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501657 · Cited by 163
Kalaora, S., Lee, J. S., Barnea, E., Levy, R., Greenberg, P., Alon, M., Yagel, G., Eli, G. B., Oren, R., Peri, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14639-9 · Cited by 162
Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161
Chapiro, J., Claverol, S., Piette, F., Ma, W., Stroobant, V., Guillaume, B., Gairin, J.-E., Morel, S., Burlet-Schiltz, O., Monsarrat, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.1053 · Cited by 160
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe2606 · Cited by 160
T Cell Receptor Signaling: Beyond Complex Complexes
Huang, Y., & Wange, R. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400012200 · Cited by 159
Driving T-cell immunotherapy to solid tumors
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 159
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 158
Chaux, P., Luiten, R. M., Demotte, N., Vantomme, V., Stroobant, V., Traversari, C., Russo, V. E. A., Schultz, E. S., Cornelis, G. R., Boon, T., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2928 · Cited by 156
Rosenzweig, M. A., Connole, M., Glickman, R. L., et al. (2001) · Blood · doi:10.1182/blood.v97.7.1951 · Cited by 144
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01786-3 · Cited by 144
Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Butler, M. O., & Hirano, N. (2013) · Immunological Reviews · doi:10.1111/imr.12129 · Cited by 132
Davis, J. L., Theoret, M. R., Zheng, Z., Lamers, C. H. J., Rosenberg, S. A., & Morgan, R. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1280 · Cited by 132
Nakazawa, Y., Huye, L. E., Dotti, G., Foster, A. E., Vera, J. F., Manuri, P. R., June, C. H., Rooney, C. M., & Wilson, M. H. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad762b · Cited by 130
Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 127
Sommermeyer, D., & Uckert, W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902055 · Cited by 126
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich, E., Sabo, E., Lavie, O., Mazareb, S., Spagnoli, G. C., & Resnick, M. B. (2003) · PubMed · Cited by 123
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire
Ho, W., Nguyen, H., Wölfl, M., Kuball, J. H. E., & Greenberg, P. D. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.11.023 · Cited by 122
Schultz, E. S., Chapiro, J., Lurquin, C., Claverol, S., Burlet‐Schiltz, O., Warnier, G., Russo, V. E. A., Morel, S., Lévy, F., Boon, T., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011974 · Cited by 122
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Malekzadeh, P., Yossef, R., Cafri, G., Paria, B. C., Lowery, F. J., Jafferji, M. S., Good, M. L., Sachs, A., Copeland, A. R., Kim, S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1874 · Cited by 117
Birkholz, K., Hombach, A. A., Krug, C., Reuter, S., Kershaw, M. H., Kämpgen, E., Schuler, G., Abken, H., Schaft, N., & Dörrie, J. (2009) · Gene Therapy · doi:10.1038/gt.2008.189 · Cited by 116
Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies
Stone, J. D., & Kranz, D. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00244 · Cited by 116
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
PROPPER, D. J., Chao, D., Braybrooke, J. P., Bahl, P., Thavasu, P., Balkwill, F. R., Turley, H., Dobbs, N. A., Gatter, K. C., Talbot, D. C., et al. (2003) · PubMed · Cited by 115
Adoptive Immunotherapy for EBV-associated Malignancies
Gottschalk, S. M., Heslop, H. E., & Rooney, C. M. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400002202 · Cited by 114
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
Bajgain, P., Tawinwung, S., Fleckenstein, L., Sukumaran, S., Watanabe, N., Hoyos, V., Lulla, P., Brenner, M. K., Leen, A. M., & Vera, J. F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0347-5 · Cited by 110
Self-citationAn Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V. V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 106
Nowicki, T. S., Berent-Maoz, B., Cheung-Lau, G. C., Huang, R., Wang, X., Tsoi, J., Kaplan‐Lefko, P. J., Cabrera, P. V., Tran, J., Pang, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3496 · Cited by 106
Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells
Voss, R.-H., Willemsen, R. A., Kuball, J. H. E., Grabowski, M., Engel, R., Intan, R. S., Guillaume, P., Romero, P. J., Huber, C. H., & Theobald, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.391 · Cited by 103
Sanderson, J. P., Crowley, D., Wiedermann, G. E., Quinn, L. L., Crossland, K. L., Tunbridge, H. M., Cornforth, T. V., Barnes, C. S., Ahmed, T., Howe, K., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682381 · Cited by 103
Gerdemann, U., Katari, U. L., Christin, A., Cruz, C. C., Tripic, T., Rousseau, A., Gottschalk, S. M., Savoldo, B., Vera, J. F., Heslop, H. E., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.167 · Cited by 98
Stadtmauer, E. A., Faitg, T. H., Lowther, D. E., Badros, A. Z., Chagin, K., Dengel, K., Iyengar, M. K., Melchiori, L., Navenot, J., Norry, E., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000194 · Cited by 93
Abrams, S. I., Khleif, S. N., Bergmann-Leitner, E. S., Kantor, J. A., Chung, Y., Hamilton, J. M., & Schlom, J. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1224 · Cited by 91
Haga-Friedman, A., Horovitz‐Fried, M., & Cohen, C. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103020 · Cited by 89
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens
Hebeisen, M., Allard, M., Gannon, P. O., Schmidt, J., Speiser, D. E., & Rufer, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00582 · Cited by 87
Nalawade, S. A., Shafer, P. W., Bajgain, P., McKenna, M. K., Ali, A., Somes, L. K., Joubert, J., Gottschalk, S. M., Watanabe, N., Leen, A. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003237 · Cited by 85
Self-citationSebestyén, Z., Schooten, E., Sals, T., Zaldívar, I., José, E. S., Alarcón, B., Bobisse, S., Rosato, A., Szöllõsi, J., Gratama, J. W., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7736 · Cited by 82
Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes
Guillaume, B., Stroobant, V., Bousquet, M., Colau, D., Chapiro, J., Parmentier, N., Dalet, A., & den Eynde, B. J. V. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103213 · Cited by 82
Cho, S., Kim, N., Sohn, H., Lee, S. K., Oh, S. T., Lee, H.-J., Cho, H.-I., Yim, H. W., Jung, S. E., Park, G., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.91 · Cited by 81
Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition
Bialer, G., Horovitz‐Fried, M., Ya’acobi, S., Morgan, R. A., & Cohen, C. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902047 · Cited by 81
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 80
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
Feng, J., Xu, H.-C., Cinquina, A., Wu, Z., Chen, Q., Zhang, P., Wang, X., Shan, H., Xu, L., Zhang, Q., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10092-9 · Cited by 77
Analysis of CAR-Mediated Tonic Signaling
Calderón, H., Mamonkin, M., & Guedan, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0146-4_17 · Cited by 76
Functional three-domain single-chain T-cell receptors.
Chung, S., Wucherpfennig, K. W., Friedman, S., Hafler, D. A., & Strominger, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12654 · Cited by 75
Bethune, M. T., Li, X., Yu, J., McLaughlin, J., Cheng, D., Mathis, C., Moreno, B. H., Woods, K., Knights, A. J., García-Díaz, Á., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810653115 · Cited by 75
Domain-swapped T cell receptors improve the safety of TCR gene therapy
Bethune, M. T., Gee, M. H., Bunse, M., Lee, M. S., Gschweng, E. H., Pagadala, M. S., Zhou, J., Cheng, D., Heath, J. R., Kohn, D. B., et al. (2016) · eLife · doi:10.7554/elife.19095 · Cited by 73
Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
Morita, D., Nishio, N., Saito, S., Tanaka, M., Kawashima, N., Okuno, Y., Suzuki, S., Matsuda, K., Maeda, Y., Wilson, M. H., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.003 · Cited by 72
Survivin-specific T cell receptor targets tumor but not T cells
Arber, C., Feng, X., Abhyankar, H. A., Romero, E., Wu, M., Heslop, H. E., Barth, P., Dotti, G., & Savoldo, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75876 · Cited by 72
Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.195 · Cited by 69
Lu, Y., Zheng, Z., Lowery, F. J., Gartner, J. J., Prickett, T. D., Robbins, P. F., & Rosenberg, S. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002595 · Cited by 69
Oda, S. K., Daman, A. W., Garcia, N. M., Wagener, F. D., Schmitt, T. M., Tan, X., Chapuis, A. G., & Greenberg, P. D. (2017) · Blood · doi:10.1182/blood-2017-04-777052 · Cited by 68
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 67
The emerging role of γδ T cells in cancer immunotherapy
Nussbaumer, O., & Koslowski, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.002 · Cited by 67
Coreceptors and TCR Signaling – the Strong and the Weak of It
Mørch, A. M., Bálint, Š., Santos, A. M., Davis, S. J., & Dustin, M. L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.597627 · Cited by 67
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains
Aggen, D. H., Chervin, A. S., Schmitt, T. M., Engels, B., Stone, J. D., Richman, S. A., Piepenbrink, K. H., Baker, B. M., Greenberg, P. D., Schreiber, H. W., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.104 · Cited by 64
Spear, T. T., Evavold, B. D., Baker, B. M., & Nishimura, M. I. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02401-0 · Cited by 64
Hasim, A., Abudula, M., Aimiduo, R., Ma, J., Jiao, Z., Akula, G., Wang, T., & Abudula, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044952 · Cited by 60
Deniger, D. C., Pasetto, A., Tran, E., Parkhurst, M. R., Cohen, C. J., Robbins, P. F., Cooper, L. J. N., & Rosenberg, S. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.51 · Cited by 59
Improving T Cell Receptor On-Target Specificity via Structure-Guided Design
Hellman, L. M., Foley, K. C., Singh, N. K., Alonso, J. A., Riley, T. P., Devlin, J. R., Ayres, C. M., Keller, G. L. J., Zhang, Y., Kooi, C. W. V., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.010 · Cited by 59
Voss, R.-H., Thomas, S., Pfirschke, C., Hauptrock, B., Klobuch, S., Kuball, J. H. E., Grabowski, M., Engel, R., Guillaume, P., Romero, P. J., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254078 · Cited by 54
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.
Neal, L. R., Bailey, S. R., Wyatt, M. M., Bowers, J. S., Majchrzak, K., Nelson, M. H., Haupt, C., Paulos, C. M., & Varela, J. C. (2017) · PubMed · Cited by 54
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 53
Moore, T. V., Wagner, C. R., Scurti, G. M., Hutchens, K. A., Godellas, C. V., Clark, A. L., Kolawole, E. M., Hellman, L. M., Singh, N. K., Huyke‐Hernández, F. A., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2073-0 · Cited by 50
Willcoj, B. E., Gao, G. F., Wyer, J. R., O'callaghan, C. A., Jakobsen, B. K., Boulter, J. M., Bell, J. I., Jones, E. Y., & Van Der Merwe, P. A. (1999) · Protein Science · doi:10.1110/ps.8.11.2418 · Cited by 49
Govers, C., Sebestyén, Z., Roszik, J., van Brakel, M., Berrevoets, C., Szöőr, Á., Panoutsopoulou, K., Broertjes, M., Van, T., Vereb, G., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302074 · Cited by 48
Krshnan, L., Park, S., Im, W., Call, M. J., & Call, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611445113 · Cited by 48
A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy
Cho, H.-I., Kim, U.-H., Shin, A.-R., Won, J.-N., Lee, H.-J., Sohn, H., & Kim, T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.475 · Cited by 48
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“Such a strategy deflects T cell specificity to recognize specific antigens in the context of HLA presentation in any subcellular compartment [109].”
Background
Metadata
- Authors
- Shafer, P., Kelly, L. M., & Hoyos, V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-03-03
- Volume
- 13
- Pages
- 835762-835762
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4214927528
- Cited by
- 270
- References
- 217
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.